Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Iamarangerboy who wrote (9824)	11/7/2006 11:52:21 AM
From: Iamarangerboy	Read Replies (1) of 10280

XOPENEX HFA(R) Data to Be Presented at American College of Allergy, Asthma and Immunology Annual Meeting Nov 7 2006, 6:00 AM EST BIOWIRE Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA(R) (levalbuterol tartrate) Inhalation Aerosol will be presented at the American College of Allergy, Asthma and Immunology annual meeting in Philadelphia on November 11 and 12, 2006. The poster entitled, "Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Patients with Asthma" will be displayed in Exhibit Hall D of the Pennsylvania Convention Center. The investigator will be available to discuss the poster from 12:00 to 1:00 p.m. ET on both days. genengnews.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next